Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
IPO Year: 2007
Exchange: NASDAQ
Website: insulet.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
| 12/21/2023 | $180.00 → $238.00 | Neutral → Outperform | Robert W. Baird |
| 12/4/2023 | $185.00 → $234.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/2/2023 | $260.00 → $240.00 | Hold → Buy | Jefferies |
| 8/21/2023 | $320.00 → $219.00 | Outperform → Neutral | Robert W. Baird |
| 8/21/2023 | $273.00 → $265.00 | Neutral → Buy | Citigroup |
| 5/30/2023 | $343.00 | Equal-Weight | Morgan Stanley |
| 1/26/2023 | Peer Perform | Wolfe Research |
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 di
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic cal
Jury awards $452M in damages Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. ("EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of Massachusetts in the matter of Insulet Corporation vs. EOFlow et al., a jury verdict was returned in favor of Insulet on December 3, 2024. The jury found that EOFlow and several other defendants misappropriated Insulet's trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. "We are excited to announce that Omnipod 5, the only AID system indicated for both type 1 and type 2 diabetes, is now integrated with Abbott's FreeStyle Libre 2 Plus sensor in the U.S. This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod th
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m. The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:45 p.m. To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will als
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
Insulet is the first and only company to offer a tubeless automated insulin delivery (AID) system with full control from a compatible iPhone or Android™ phone Provides more choice and added convenience for Omnipod 5 users Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the full market release of the Omnipod 5 App for iPhone® in the U.S. Now available to download for free on the Apple App Store, the App allows users to fully control their Omnipod 5 Automated Insulin Delivery System (Omnipod 5) from their compatible iPhone1. For example, users can bolus for a meal, chan
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes. The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes and reduce stigma.The campaign is from the diaTribe Foundation, a nonprofit dedicated to diabetes education and advocacy, and a leader in the movement to end diabetes stigma. "We don't want to lecture people into changing their stigmatizing behavior, we don't believe that will be very effe
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
10-Q - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
SD - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic cal
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
Raising Full Year Revenue, Gross Margin and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $480.4 million, an increase of 26.3%, or 26.5% in constant curr
Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary revenue results for the three months ended June 30, 2024. The Company plans to report full second quarter 2024 financial results on August 8, 2024, as planned, and host a conference call that day at 4:30 p.m. (Eastern Time). Preliminary Second Quarter Revenue Highlights: Second quarter 2024 revenue of $488 million, up 23%, compared to $397 million in the prior year, exceeds the guidance range of
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
Raising Full Year Revenue and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2024. First Quarter Financial Highlights: First quarter 2024 revenue of $441.7 million, up 23.3%, or 22.8% in constant currency1, compared to $358.1 million in the prior year, exceeds the guidance range of 17% to 20% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $433.0 million, an increase of 21.1%, or 20.5% in constant currency U.S. Omnipod revenue of $31
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210
Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue of $1.7 billion, up 30.0%, or 29.6% in constant currency, compared to $1.3 billion in the prior year, exceeds the guidance range of 26% to 27% in constant currency. Full year 2023 revenue includes an estimated $20 million to $25 million related to U.S. pharmacy wholesaler orders that were accelerated from the f
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic call
Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00
Redburn Atlantic initiated coverage of Insulet with a rating of Buy and set a new price target of $235.00
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $200.00
Robert W. Baird upgraded Insulet from Neutral to Outperform and set a new price target of $238.00 from $180.00 previously
Morgan Stanley upgraded Insulet from Equal-Weight to Overweight and set a new price target of $234.00 from $185.00 previously
Jefferies upgraded Insulet from Hold to Buy and set a new price target of $240.00 from $260.00 previously
Robert W. Baird downgraded Insulet from Outperform to Neutral and set a new price target of $219.00 from $320.00 previously
Citigroup upgraded Insulet from Neutral to Buy and set a new price target of $265.00 from $273.00 previously
Morgan Stanley resumed coverage of Insulet with a rating of Equal-Weight and set a new price target of $343.00
Wolfe Research initiated coverage of Insulet with a rating of Peer Perform
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today's announcement concludes an extensive search process conducted by the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320426712/en/Ana Maria Chadwick, Chief Financial Officer (Photo: Business Wire) "We are thrilled to welcome Ana to Insulet," said Jim Hollingshead, President and Chief Executive Officer. "She is an ex
Chuck Alpuche Appointed as COO, Peter Griffin as SVP of Operations, Scott Elliott as CLO, Daniel Davis as CSO Seasoned leaders poised to advance growth and mission to elevate patient care through significant operational and industry experience Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Chuck Alpuche as Chief Operating Officer (COO), Peter Griffin as Senior Vice President of Operations, Scott Elliott as Chief Legal Officer (CLO), and Daniel Davis as Chief Strategy Officer (CSO). "This is an inflection point of operational scale and excellence
Flavia Pease and Timothy Stonesifer to join Board of Directors Shacey Petrovic and Corinne Nevinny to retire from the Board at the Company's 2024 Annual Meeting Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the following appointments to the Company's Board of Directors, effective January 18: Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories Timothy Stonesifer, Chief Financial Officer at Alcon Inc. In addition, the Company announced Shacey Petrovic and Corinne Nevinny will retire from the Board during th
Petrovic brings significant leadership in the global medical technology sector Imperative Care, Inc. a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Shacey Petrovic to the company's Board of Directors, effective immediately. "We have been intentional in assembling the right balance of investors, executives, and industry experiences, on our board, each with their own unique and complimentary expertise and passion in elevating patient care," said Fred Khosravi, Chairman and CEO of Imperative Care. "Shacey has dedicated her career to improving care for patients while
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Elizabeth "Bess" Weatherman has been appointed to the Company's Board of Directors. Ms. Weatherman will stand for election by stockholders at the Company's 2022 Annual Meeting. In addition, Ms. Weatherman has been named to the Compensation Committee of the Board. Ms. Weatherman is a Special Limited Partner of Warburg Pincus LLC. Since joining Warburg Pincus in 1988, Ms. Weatherman has primarily been focused on investment activities in the healthcare sector. She led the firm's Healthcare Group from 2008 to 2015 and was pr
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights' Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplished industry veteran, and we are thrilled to welcome her to our Board," said Eric Hobbs, Ph.D., chief executive officer of Berkeley Lights. "With more than two decades of medical device, biotech and pharmaceutical experience, Dr. Hopfield brings to Berkeley Lights valuable strategic insight and a strong focus on performance to drive our unrivaled ability to understand c